Physician Acceptance of the NeuTrace System for Cardiac Electroanatomic Mapping

Atrial Fibrillation Clinical Trial

Official title:

Physician Acceptance of the NeuTrace System for Cardiac Electroanatomic Mapping

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05214170
• Other study ID #: NT001
• Status: Recruiting
• Phase: N/A
• Start date: June 7, 2021
• Est. completion date: June 7, 2024

Study information

• Verified date: April 2023
• Source: NeuTrace, Inc.
• Contact: Pradeep S Rajendran, MD/PhD
• Phone: 6303061864
• Email: prajendran[@]neucures.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The trial is a prospective, non-randomized, single-arm feasibility trial to evaluate physician acceptance of the NeuTrace System v1.0 for cardiac electroanatomic mapping.

Description:

Arrhythmias, or abnormal heart rhythms, are a major cause of morbidity and mortality worldwide. In patients with arrhythmias, electrophysiology (EP) studies are often performed to assess the electrical system of the heart. Since its introduction in the 1990s, electroanatomic mapping has become a cornerstone of EP studies. Electroanatomic mapping systems allow for non-fluoroscopic navigation of the heart and the creation of three-dimensional (3D) anatomic and electroanatomic maps. These maps facilitate diagnosing and treating arrhythmias.

The NeuTrace System is a cardiac EP mapping system that is intended to be used during catheter-based atrial and ventricular mapping procedures. The system is designed to acquire and analyze data points and use this information to display 3D anatomical and electroanatomic mapping of the human heart. The system is used with a compatible, marketed magnetic sensor-enabled catheter and compatible EP recording system to acquire the location information and local electrogram needed to create the cardiac maps. The purpose of the trial is to evaluate physician acceptance and feasibility of the NeuTrace System v1.0 for cardiac electroanatomic mapping.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: June 7, 2024
• Est. primary completion date: May 7, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patient with standard indications for an electrophysiology study and/or catheter ablation per European Heart Rhythm Association/Heart Rhythm Society) guidelines and/or judgement of the investigator

• Age 18 to 80

• Signed Informed Consent Form

Exclusion Criteria:

• Any cardiac surgery, myocardial infarction, percutaneous coronary intervention/percutaneous transluminal coronary angioplasty, or coronary artery stenting which occurred during the 90-day interval preceding the date that participant signed the Informed Consent Form

• Unstable angina

• NHYA class III or IV congestive heart failure and/or known left ventricular ejection fraction less than 45%

• Thrombocytosis, thrombocytopenia

• Contraindication to anticoagulation therapy

• Active systemic infection

• Cryoglobulinemia

• Known reversible causes of arrhythmia

• Any cerebral ischemic event (stroke or transient ischemic attacks) which occurred during the 180-day interval preceding the date the participant signed the Informed Consent Form, or any known unresolved complications from the previous stroke/transient ischemic attack

• Pregnancy

• Unwilling or unable to comply fully with study procedures

Related Conditions & MeSH terms

• Arrhythmias, Cardiac
• Atrial Fibrillation
• Atrial Flutter

Intervention

Device:
• Electroanatomic mapping with the NeuTrace System
Patients with arrhythmias undergo electroanatomic mapping with the NeuTrace System.

Locations

Country	Name	City	State
Lithuania	Vilnius University Hospital Santaros Klinikos	Vilnius

Sponsors (1)

Lead Sponsor	Collaborator
NeuTrace, Inc.

Country where clinical trial is conducted

Lithuania, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Physician rating of the electroanatomic map created by the NeuTrace System via a questionnaire	At the completion of each electrophysiology study, the principal investigator will be asked to complete a questionnaire in which he or she qualitatively rates the electroanatomic map created by the NeuTrace System on a numeric scale from 1 to 5 (1 = not satisfied, 5 = very satisfied).	Immediately post-procedure
Secondary	Physician rating of catheter visibility during electroanatomic mapping with NeuTrace System via a questionnaire	At the completion of each electrophysiology study, the principal investigator will be asked to complete a questionnaire in which he or she qualitatively rates the visibility of the catheter during electroanatomic mapping with the NeuTrace System on a numeric scale from 1 to 5 (1 = not satisfied, 5 = very satisfied).	Immediately post-procedure
Secondary	Physician rating of the accuracy of the anatomical map created with the NeuTrace System compared to an image obtained via computerized tomography, magnetic resonance imaging, or intracardiac echocardiography via a questionnaire	Each participant will have an image obtained of their heart either pre-procedurally via computed tomography or magnetic resonance imaging, or intraprocedurally via intracardiac echocardiography. At the completion of each electrophysiology study, the principal investigator will be asked to complete a questionnaire in which he or she qualitatively rates the accuracy of the electroanatomic map created by the NeuTrace System with the image of the heart obtained via computerized tomography, magnetic resonance imaging, or intracardiac echocardiography.	Immediately post-procedure
Secondary	Measurement of the shift in the electroanatomic during the procedure with the NeuTrace System	Shift refers to the movement of an electroanatomic map during the procedure (e.g., the patient moves in relation to the magnetic field). During each electrophysiology study, the principal investigator will annotate a point on the electroanatomic map with the NeuTrace System (X at time 1). The principal investigator will return to and again annotate that same point on the electroanatomic map 20 minutes later (X at time 2). The location of the point will be confirmed via intracardiac echocardiography. The distance between the points (X at time 1 and X at time 2) will be measured on the NeuTrace System in millimeters.	Immediately post-procedure
Secondary	Measurement of the drift in the electroanatomic during the procedure with the NeuTrace System	Drift refers to the movement of an electroanatomic map during the procedure due to interference with the magnetic field. During each electrophysiology study, the principal investigator will annotate a point on the electroanatomic map with the NeuTrace System (X1). The principal investigator will then move the X-ray image intensifier (a common source of interference) to a fixed interval above the magnetic field generator and again annotate that same point on the electroanatomic map (X2). The distance between the points (X1 and X2) will be measured on the NeuTrace System in millimeters.	Immediately post-procedure
Secondary	Physician rating of the manual annotation of ablation points with the NeuTrace System via a questionnaire	At the completion of each electrophysiology study, the principal investigator will be asked to complete a questionnaire in which he or she qualitatively rates the manual annotation of ablations points during electroanatomic mapping with the NeuTrace System on a numeric scale from 1 to 5 (1 = not satisfied, 5 = very satisfied).	Immediately post-procedure
Secondary	Physician rating of the total mapping time with the NeuTrace System via a questionnaire	Total mapping time refers to the time taken to create an electroanatomic map. At the completion of each electrophysiology study, the principal investigator will be asked to complete a questionnaire in which he or she qualitatively rates the total mapping time with the NeuTrace System on a numeric scale from 1 to 5 (1 = not satisfied, 5 = very satisfied).	Immediately post-procedure
Secondary	Number of participants with serious adverse events at 30-day post-procedure telephone follow up	Each participant will have a telephone follow-up at 30 days post-procedure for monitoring of serious adverse events. The number of participants with a serious adverse events will be measured.	30 days post-procedure